HLS Therapeutics to Host First Quarter Fiscal 2022 Financial Results Conference Call

TORONTO, April 28, 2022 /CNW/ – HLS Therapeutics Inc. (“HLS” or the “Company”) HLSannounces that it will release its financial results for the first quarter of fiscal 2022 on Thursday, May 5, 2022. The Company will hold a conference call the same day at 8:30 a.m. ET to discuss their results. The call will be moderated by Mr. Gilbert Godingeneral manager and Mr. Tim HendricksonFinancial director. Slides accompanying the remarks prepared by management will be available for viewing via the webcast.

CONFERENCE ID:

40019581

DATE:

Thursday, May 5, 2022

WEATHER:

8:30 a.m. ET

NUMBER TO DIAL:

1-888-664-6392 or 416-764-8659

WEBCAST LINK:

https://produceredition.webcasts.com/starthere.jsp?ei=1544747&tp_key=e96e137a22

RECORDED REPLAY:

1-888-390-0541 or 416-764-8677

REVIEW CODE:

019581

The recorded replay will be available for 14 days and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of the HLS Therapeutics website at www.hlstherapeutics.com. Please tune in at least 15 minutes before the conference call to ensure enough time for any software downloads that may be required to listen to the webcast.

ABOUT HLS THERAPEUTIC INC.

Founded in 2015, HLS is a pharmaceutical company focused on acquiring and commercializing late-stage, commercial-stage branded pharmaceutical products established in North American markets. HLS focuses on products targeting the central nervous system and cardiovascular therapeutic areas. The HLS leadership team is comprised of seasoned pharmaceutical executives with strong track records of success in these therapeutic areas and managing products at each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

View original content: http://www.newswire.ca/en/releases/archive/April2022/28/c1534.html

Michael P. Boser